EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit

Ensembl ID : ENSMOCG00000005267
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta1 Subunit

Ensembl ID : ENSMOCG00000014692
Gene Symbol: GABRB1
3 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSMOCG00000000191
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta3 Subunit

Ensembl ID : ENSMOCG00000022638
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Delta Subunit

Ensembl ID : ENSMOCG00000008574
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma2 Subunit

Ensembl ID : ENSMOCG00000003137
Gene Symbol: GABRG2
3 Cross references
204 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma3 Subunit

Ensembl ID : ENSMOCG00000013639
Gene Symbol: GABRG3
3 Cross references
255 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Pi Subunit

Ensembl ID : ENSMOCG00000022600
Gene Symbol: GABRP
3 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Ensembl ID : ENSMOCG00000015386
Gene Symbol: GABRQ
3 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSMOCG00000003335
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSMOCG00000021735
Gene Symbol: GABBR2
3 Cross references
241 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMOCG00000015992
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).